Smart Equity Invest

← Results dashboard

Q2 FY27 · NSE: TATVA

Tatva Chintan Pharma Chem

Results filed 19 October 2026 · Market cap ₹3,845 crore · PE 60.2

GrowthGuidance maintainedPresentation only

Revenue
+75.9%
on a year ago
EBITDA
+83.1%
on a year ago
Profit to shareholders
+116.2%
on a year ago
EBITDA margin
18.7%
−0.6 pts on last quarter

Tatva Chintan reported record consolidated quarterly revenue of ₹2,173 Mn in Q2 FY27, up 76% YoY, driven primarily by strong demand for Structured Directing Agents under EURO 7 regulations. Operating margins remained constrained near 19% as severe solvent cost spikes of 60%-100% and a doubling of transatlantic/European freight rates countered operating leverage benefits. Working capital expansion caused short-term borrowings to climb to ₹1,655.30 Mn, while management expects input cost pressures to normalize by Q3 FY27.

Tatva Chintan Pharma Chem Limited, Q2 FY27₹ crore, consolidated
Q2 FY27Q1 FY27vs previous quarterQ2 FY26vs a year ago
Revenue217167+30.1%124+75.9%
Operating profit (EBIT)29.921.73+37.6%13.17+127.0%
Operating margin13.8%13.0%+75 bps10.7%+310 bps
Other income1.752.78−37.1%1.01+73.3%
Exceptional items0−1.32–0–
Profit before exceptional items and tax28.9422.43+29.0%13.66+111.9%
Profit to shareholders21.4515.98+34.2%9.92+116.2%
Earnings per share (₹)9.176.83+34.3%4.24+116.3%

Source: Tatva Chintan Pharma Chem Limited’s filing to NSE, 19 October 2026. Operating profit is revenue less every expense except interest, so it leaves out other income and exceptional items. n.m.: not meaningful, because the earlier figure was zero or negative, or the latest one is a loss.

These notes are from the presentation and press release. The concall transcript isn’t filed yet; the notes are rewritten when it is.

What stood out

  • Highest-ever quarterly revenue achieved with 76% YoY top-line growth
    SourceRevenue from operations reached ₹2,173 Mn in Q2 FY27 compared to ₹1,235 Mn in Q2 FY26 (+76% YoY, +30% QoQ) (Updated Presentation, original page 11).
  • SDA demand driven by EURO 7 emission standards implementation
    SourceIn Structured Directing Agents, 'the implementation of EURO 7 emission standards is already translating into a meaningful contribution to our sales' (CMD Message, original page 6).
  • Margin pressure from solvent price spikes and doubled freight rates
    Source'erratic short supplies in some of the solvents which has led to a price increase in these solvents by 60%-100%' and 'rampant increase in global freights, especially, in certain sectors of US and Europe where the increase is more than 100%' (CMD Message, original page 5).

Guidance

MetricGuidancePeriod
Revenue Growth Momentum
Source'We foresee the revenue trend growth with similar momentum over the next quarters' (CMD Message, original page 5).
Foresee revenue trend growth with similar momentum over the next quartersNext quarters of FY27
EBITDA Margin
Source'We expect it to normalise withing the third quarter. We foresee... EBITDA margin to resume its healthy trajectory' (CMD Message, original page 5).
Expected to resume healthy trajectory as solvent prices and freights normalize in Q3Q3 FY27 and beyond

Tailwinds

  • Strong demand in SDA driven by EURO 7 transition
    SourceSDA accounted for 45% of Q2 FY27 revenue, driven by regulatory adoption of EURO 7 emission standards (Updated Presentation, original pages 6 and 12).
  • Commercialisation traction in Pharma and Agro Intermediates (PASC)
    Source'recently commercialised agro products performing well and our pharma product beginning to contribute to the business', bringing PASC to 30% of Q2 FY27 revenue (CMD Message, original page 6; Updated Presentation, original page 12).
  • Operating leverage in personnel and overhead costs
    Source'achieved significant operating leverage which is depicted by decrease in employee cost by 2% accompanied by decrease in other expenses by 2%' (CMD Message, original page 5).

Headwinds

  • Sharp surge in input raw material solvent prices
    SourcePrice increases in high-volume solvents of 60%-100% due to erratic short supplies pressured overall raw material costs (CMD Message, original page 5).
  • Escalation in international freight rates
    SourceGlobal freight costs increased by over 100% in certain US and European trade sectors (CMD Message, original page 5).
  • Surge in working capital and short-term debt
    SourceInventories rose to ₹2,489.10 Mn and trade receivables rose to ₹1,783.77 Mn as of September 30, 2026, leading to short-term borrowings rising to ₹1,655.30 Mn from ₹1,153.63 Mn in March 2026 (Updated Presentation, original pages 14-15).

New businesses and products

new product · Advancing through development, validation, and customer qualification

Semiconductor Chemicals development portfolio

Expected benefit
Building blocks of a new phase of growth and future revenue stream
Risks
Lengthy customer qualification and validation cycles
Source'we continue to make encouraging progress across all five products in our development portfolio, each advancing well through its respective stages of development, validation and customer qualification' (CMD Message, original page 7).

capacity expansion · Progressing in line with planned schedule

Greenfield manufacturing facility

Expected benefit
Provide additional manufacturing capacity for organic expansion and commercialisation of pipeline molecules
Risks
Execution and timely commissioning
Investment
CWIP stood at ₹428.27 Mn as of 30 September 2026 (Updated Presentation, original page 15)
Source'our new greenfield project is progressing in line with the planned schedule... providing the additional manufacturing capacity required to accommodate the organic expansion' (CMD Message, original page 7).

new product · Progressing towards commercialisation and scaling up

Electrolyte Salts & Solutions for hybrid-battery and energy-storage applications

Expected benefit
Broaden market participation in energy storage and super-capacitor applications
Risks
Adoption speed in EV and energy storage segments
Source'hybrid-battery application is progressing towards commercialisation, and additional products are being scaled up for energy-storage applications' (CMD Message, original page 6).

Things to check

  • Revenue up over 60%: check for an acquisition or a weak year-ago quarter
  • Substantial increase in short-term debt to fund working capital
    SourceShort-term borrowings increased by 43.5% from ₹1,153.63 Mn in March 2026 to ₹1,655.30 Mn in September 2026, reflecting high inventory (₹2,489.10 Mn) and receivables (₹1,783.77 Mn) (Updated Presentation, original pages 14-15).
  • Presentation errata regarding leverage and RoE metrics
    SourceAn annexure was filed correcting H1 FY27 RoE from 2.6% to 6.3% and Debt to EBITDA from 4.30x to 1.16x annualized (Updated Presentation, original page 2).

How the call went

Not yet: there’s no transcript.

Numbers against the story

Management describes achieving 'significant operating leverage' while noting EBITDA remained at 'nearly similar levels' due to raw material and freight headwinds. In reality, absolute EBITDA grew 83% YoY (to ₹407 Mn from ₹222 Mn), but EBITDA margin was essentially flat YoY at 19% vs 18% (and down slightly QoQ), demonstrating that operating leverage benefits were largely offset by cost spikes in solvents and freights. Regarding the +60% sales growth screen flag, growth is entirely organic driven by SDA (Euro 7 transition) and PASC ramp-up, rather than acquisitions.

Sources

Notes written by gemini-3.8-flash from the documents above on 15 November 2026. They summarise what the company said and can contain mistakes: check the source passage before relying on a point. Not investment advice.